A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Trial Details

NCT ID

NCT05967689

Phase

PHASE2

Sponsor

Taiho Oncology, Inc.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

TAS6417
CYP Cocktail
Transporter Cocktail

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Duarte, California, United States|34.13945,-117.97729
Boston, Massachusetts, United States|42.35843,-71.05977
Las Vegas, Nevada, United States|36.17497,-115.13722
Basking Ridge, New Jersey, United States|40.70621,-74.54932

Key Eligibility Criteria

Written informed consent.
≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.
Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
Cohort A participants:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →